Pet hypothyroidism therapy sales will expand through 2036, with levothyroxine sodium replacement therapy holding 49.7% of the therapy segment in 2026. The market was valued at USD 216.20 million in 2025 and is expected to reach USD 343.54 million by 2036, creating an incremental opportunity of USD 118.04 million.